Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H12Cl2N6O |
| Molecular Weight | 435.266 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(=CC(OC2=C(Cl)C=CC3=C2C=NN3CC4=NNC5=NC=CC=C45)=C1)C#N
InChI
InChIKey=FZBAOOQVQXATRL-UHFFFAOYSA-N
InChI=1S/C21H12Cl2N6O/c22-13-6-12(9-24)7-14(8-13)30-20-16-10-26-29(19(16)4-3-17(20)23)11-18-15-2-1-5-25-21(15)28-27-18/h1-8,10H,11H2,(H,25,27,28)
MK-6186 is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) which displays subnanomolar potency against wild-type (WT) HIV virus and the two most prevalent NNRTI-resistant RT mutants (K103N and Y181C) in biochemical assays. In addition, it showed excellent antiviral potency against K103N and Y181C mutant viruses. In 2010 MK-6186 was studied in phase I clinical trials but no further development reports were published.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
K3978U665M
Created by
admin on Sat Dec 16 08:24:08 UTC 2023 , Edited by admin on Sat Dec 16 08:24:08 UTC 2023
|
PRIMARY | |||
|
1034708-72-9
Created by
admin on Sat Dec 16 08:24:08 UTC 2023 , Edited by admin on Sat Dec 16 08:24:08 UTC 2023
|
ALTERNATIVE | |||
|
DB12999
Created by
admin on Sat Dec 16 08:24:08 UTC 2023 , Edited by admin on Sat Dec 16 08:24:08 UTC 2023
|
PRIMARY | |||
|
24988948
Created by
admin on Sat Dec 16 08:24:08 UTC 2023 , Edited by admin on Sat Dec 16 08:24:08 UTC 2023
|
PRIMARY | |||
|
1034474-19-5
Created by
admin on Sat Dec 16 08:24:08 UTC 2023 , Edited by admin on Sat Dec 16 08:24:08 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
